Private equity firm Blackstone (BX.N) is close to finalizing a deal to sell Japanese supplement maker Alinamin Pharmaceutical to North Asian buyout fund MBK Partners for 350 billion yen ($2.17 billion), according to a source familiar with the matter. The deal, expected to be signed soon, follows Blackstone’s acquisition of Alinamin in August 2020 when it was a subsidiary of Takeda Pharmaceutical (4502.T).
MBK Partners plans to leverage its expertise in consumer goods acquisitions to enhance Alinamin’s value. Alinamin, previously known as Takeda Consumer Healthcare Co, offers over-the-counter medicines in Japan. Since Blackstone’s takeover, Alinamin has expanded its presence with a new unit in Taiwan and increased overseas sales. The Nikkei first reported the planned sale, noting MBK’s strategic intentions for Alinamin’s growth.